Clients News • MC Services corporate website
paged,page-template-default,page,page-id-5522,paged-99,page-paged-99,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive




  • HPS Home Power Solutions GmbH announces first closing of its financing round at € 7.5 million
  • Ergomed plc: Board and Management Changes
  • Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis
  • nova funds: Gesundheitsaktienfonds nova Steady HealthCare erzielt 2018 erneut sehr gutes Ergebnis
  • Medigene AG: Medigene participates at four upcoming conferences
  • Allergy Therapeutics announces business development ppdate and publication date of half year results for FY 2018/2019
  • Newron Pharmaceuticals: Commercialization partner Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for Parkinson’s disease in Canada
  • Adocia confirms its financial calendar for 2019
  • Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance
  • Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554